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MODERN APPROACHES TO THE TREATMENT OF ENDOMETRIOID CYSTS BEFORE 
CONTROLLED OVARIAN STIMULATION PROTOCOLS
The article is devoted to the current problem of endometriosis-associated infertility. In recent years, a great deal of information 
has been accumulated on the etiology, diagnosis and treatment of genital endometriosis and endometriosis-associated infertility. 
According to world studies, endometriosis remains one of the most pressing problems in modern gynecology. This is evidenced 
by statistics showing that the disease occurs in every 10 women of fertile age, and a total of 176 million women worldwide. Ap-
proximately 20–50 % of women included in this number have a problem of infertility. Hence, the problem of this disease is not only 
a medical but also a social problem.
Conclusions. The tactics of treatment of patients with endometriosis who are planning a pregnancy and are included in the ART 
protocols are significantly different from the tactics of treatment of patients who believe that they have performed reproductive function.
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СОВРЕМЕННЫЕ ПОДХОДЫ К ЛЕЧЕНИЮ ЭНДОМЕТРИОИДНЫХ КИСТ ПЕРЕД ПРОТОКОЛАМИ КОНТРОЛИРУЕМОЙ 
ОВАРИАЛЬНОЙ СТИМУЛЯЦИИ (КОС)
Статья посвящена актуальной проблеме современности – эндометриоз-ассоциированному бесплодию. В последние 
годы накопилось много информации по этиологии, диагностике и лечению генитального эндометриоза и эндометриоз-
ассоциированного бесплодия. По данным мировых исследований, эндометриоз остается одной из наиболее актуальных 
проблем в современной гинекологии. Об этом свидетельствуют статистические данные, согласно которым это заболевание 
встречается у каждой 10-й женщины репродуктивного возраста, и в целом в 176 млн женщин во всем мире. Примерно в 
20–50 % женщин, которые входят в это число, возникает проблема бесплодия. Исходя из этого, проблематика данного 
заболевания является не только медицинской, но и социальной проблемой.
Выводы. Тактика лечения пациенток с эндометриозом, которые планируют беременность и включены в протоколы 
ВРТ, существенно отличается от тактики лечения пациенток, которые считают, что репродуктивную функцию выполнили.
Ключевые слова: эндометриоз; бесплодие; экстракорпоральное оплодотворение; склеротерапия.
СУЧАСНІ ПІДХОДИ ДО ЛІКУВАННЯ ЕНДОМЕТРІОЇДНИХ КІСТ ПЕРЕД ПРОТОКОЛАМИ КОНТРОЛЬОВАНОЇ 
ОВАРІАЛЬНОЇ СТИМУЛЯЦІЇ (КОС)
Стаття присвячена актуальній проблемі сьогодення – ендометріоз-асоційованому безпліддю. Протягом останніх років на-
копичилось багато інформації щодо етіології, діагностики та лікування генітального ендометріозу та ендометріоз-асоційованого 
безпліддя. За даними світових досліджень, ендометріоз залишається однією з найбільш актуальних проблем у сучасній 
гінекології. Про це свідчать статистичні дані, згідно з якими це захворювання зустрічається у кожної 10-ї жінки репродуктивного 
віку й загалом у 176 млн жінок у всьому світі. Приблизно у 20–50 % жінок, які входять у це число, виникає проблема безпліддя. 
З огляду на це, проблематика даного захворювання постає не лише медичною, а й соціальною проблемою.
Висновки. Тактика лікування пацієнток із ендометріозом, які планують вагітність та включені в протоколи ДРТ, суттєво 
відрізняється від тактики лікування пацієнток, які вважають, що репродуктивну функцію виконали.
Ключові слова: ендометріоз; безпліддя; екстракорпоральне запліднення; склеротерапія.
Endometriosis is a widespread, polyetiological disease 
in women of child-bearing age, which, despite the large 
amount of research and information, remains insufficiently 
studied. However, all literature sources indicate that genital 
endometriosis adversely affects the reproductive function of 
women [1]. According to various authors, the frequency of 
this disease ranges from 7 to 59 %. More accurate statistics 
indicate that endometriosis occurs in every 10 woman of 
reproductive age, and a total of 176 million women worldwide 
[1–3]. Approximately 20–50 % of women included in this number 
have a problem of infertility. Hence, the problem of this disease 
is not only a medical but also a social problem [3].
Over the last decade, there has been an increasing trend 
in the incidence of genital endometriosis, although it is dif-
ficult to draw accurate conclusions about the spread of the 
disease because there are no clear epidemiological studies.
Adverse ecological situation, pollution of the environment 
with harmful products of industrial production, in particular 
dioxins, contribute to the development and progression of 
endometriosis. In industrialized countries, the percentage 
of sick women is higher than in countries with poorly devel-
oped industry. There is also a clear gradation between the 
development of this disease in different races, in particular 
in Asian women, mostly Japanese, the percentage of this 
disease is higher than in European women, who in turn have 
endometriosis more often than the Negroid race women [4].
Regardless of the location, genital endometriosis is not 
a local but a common disease. For its development in the 
body under the influence of a number of factors (hereditary, 
neuropsychiatric, somatic pathologies, chronic inflamma-
tory processes in the genitals, changes in the function of 
the hypothalamic-pituitary-ovarian system, adrenal glands, 
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immune system, surgery on the genitals and other organs) 
should form a certain neuro-endocrine background. To date, 
no single trigger mechanism of the disease has been de-
scribed, which leads to conclusions about the multifactorial 
nature of the process [5].
Typical and common symptoms of the disease are: dys-
menorrhea and menstrual disorders (occurs in 70 % and 15 % 
of patients, respectively), pelvic pain (in 40 % of women), 
33 % of women suffer from dyspareunia, 25–60 % have 
endometriosis-associated infertility [4]. Other clinical symp-
toms include: pain during ovulation; profuse bleeding during 
menstruation; effects on pregnancy (miscarriage, premature 
birth); dark bloody discharge from the vagina before and after 
menstruation; pain in the sacrum; bloody discharge from the 
genital tract in the middle of the menstrual cycle; fatigue. In 
general, endometriosis is characterized by a variety of symp-
toms – from asymptomatic to the clinic of “acute abdomen”. 
Although the main triad of symptoms identified by the World 
Endometriosis Society is dysmenorrhea, dyspareunia and 
dyschesis. It is logical that the clinical picture of the disease 
depends on the location and prevalence of the process. 
However, modern studies show that there is no connection 
between the degree of the disease and its symptoms, the 
severity of the pain syndrome does not always correspond 
to the prevalence and size of endometrioid heterotopias 
detected by clinical and endoscopic examination [6].
For women of reproductive age, in whom endometriosis 
is much more common, infertility caused by endometriosis is 
an important problem [7]. It is caused by dysfunction of the 
fallopian tubes due to occlusion and germination of heteroto-
pias in the lumen, their uncoordinated activities; disorders in 
the system hypothalamus – pituitary – ovaries (anovulation, 
luteinization of follicles, luteal phase insufficiency); imbalance 
in the immune system, which contributes to the violation 
of the functional activity of sperm or embryo implantation; 
peritoneal adhesions; common sexual dysfunction due to 
pain (dyspareunia) [8].
The main mechanisms that explain infertility in endo-
metriosis are: violation of folliculogenesis, inferiority of the 
secretory phase, impaired fertilization, reduced likelihood of 
implantation, changes in the properties of peritoneal fluid, 
the development of the adhesive process. These patho-
physiological causes that contribute to the development of 
infertility occur as a consequence of chronic inflammatory 
processes and violations of the mechanisms of oxidative 
defense [9–11]. Inflammatory processes in turn lead to 
changes in the composition of peritoneal and follicular fluid. It 
is proved that peritoneal fluid is significantly higher in women 
with endometriosis-associated infertility than in women with 
other forms of infertility [12]. The composition of peritoneal 
fluid includes: steroid hormones of the ovary (estrogens and 
progesterones), cellular components, including endometrial 
cells, electrolytes, erythrocytes, lymphocytes, macrophages; 
each of these components produces active substances that 
provoke oxidative stress [10, 12], which in turn affects the 
quality of eggs and the process of implantation [13]. In total, 
due to the action of the cascade of all these biochemical and 
pathophysiological processes, the anatomy of the pelvic 
organs, ovarian function, embryo implantation and fertility 
are impaired [14].
Despite the fact that today all pathogenetic mechanisms 
and theories of endometriosis development have been 
deeply described, statistical data show an increase in the 
number of cases, which is the reason for continuing scientific 
research to solve this medical and social problem.
Recently, the diagnosis of the disease remains an impor-
tant focus in practice, as endometriosis is often referred to as 
“missed disease”, and the average time between the onset 
of pain and diagnosis, for example, in the United Kingdom 
of Great Britain is 8 years and 12 years in the United States 
of America [15].
The “gold” standard for the diagnosis of endometriosis is 
still a direct visualization of lesions during surgery, mainly in 
combination with histological confirmation of endometrioid 
tissue [6, 16]. This method is the most accurate, although it 
has its drawbacks: the average delay in diagnosis (from the 
onset of symptoms to the final diagnosis) grows, and the 
risks inherent in all surgical procedures with possible general 
anesthesia complications increase.
Definitely, “office”, minimally invasive diagnostics is 
considered theoretically simpler, although it is not perfect 
and remains a subject of scientific interest and a promising 
direction in the practice of specialists. Because endometriosis 
is considered a dyshormonal, immune-dependent disease, 
scientists have already proposed a sufficient number of pre-
dictors with which to diagnose endometriosis faster, in the 
early stages and without much technical difficulty [10]. But 
today such methods are qualitatively inferior to instrumental 
(colposcopy, hysteroscopy, ultrasound, CT, MRI), which not 
only confirm the existence of the process, but also with which 
you can assess the degree of tissue damage. Despite many 
studies, no biomarker or biomarker panel for a non-invasive 
diagnostic test with sufficient sensitivity and specificity has 
been confirmed so far [10, 17]. Further research is needed 
to develop a clinically useful test.
Unequivocally, to date there is no single unified tactic 
for the treatment of endometriosis. The best is an individual 
approach with a comprehensive solution to the problem of 
a woman's age, location and prevalence, severity of symp-
toms, fertility and the need to restore reproductive function, 
the presence of concomitant gynecological and somatic 
pathology, the effectiveness of previous treatment [18, 19].
Of course, the tactics of treating patients with endometrio-
sis who are planning a pregnancy and are included in ART 
protocols are different from those who believe that they have 
performed reproductive function. To date, the issue of treating 
endometriosis associated with infertility before ART programs 
remains controversial, but most are inclined to believe that:
– in the case of newly diagnosed endometriosis, drug 
therapy is recommended before in vitro fertilization (IVF);
– when recurrent endometriosis and cyst sizes of 30–40 mm, 
IVF is possible without prior surgery;
– for recurrent cysts and cysts larger than 40 mm, surgi-
cal treatment with subsequent assessment of the ovarian 
reserve is recommended;
– postoperative drug therapy is not effective and does 
not improve the incidence of pregnancy.
Drug therapy is to suppress the hypothalamic-pituitary 
system and induce the development of atrophic changes in 
the tissue of endometrioid heterotopias. For this purpose, 
use: GnRH agonists, aromatase inhibitors, COCs, proges-
togens, IUD with levonorgestrel. Also for the correction of 
immune disorders, suppression of pain, analgesics, antispas-
modics, nonsteroidal anti-inflammatory drugs are used for 
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antioxidant effect and desensitizing therapy. Unfortunately, 
conservative treatment only reduces the symptoms of the 
disease and improves the functions of the reproductive 
system for some time [20].
At present, it is technically impossible to remove the 
anatomical substrate of endometriosis by any method other 
than surgery. Therefore, it is considered the “gold standard” 
of treatment. However, even surgical treatment is not always 
appropriate, as it leaves a fairly high risk of disease recurrence 
and in most cases adversely affects the state of the ovarian 
reserve, deteriorating the quality of ovogenesis, which is critical 
for patients who want to become pregnant [21].
It is also proven that the use of IVF as a first-line therapy 
increases the pregnancy rate to 56.1 % compared with a 
significantly reduced frequency of pregnancies – 37.4 % 
during IVF after surgery [22].
The issue of endometriosis-associated infertility therapy 
has been and remains relevant. Treatment of this disease 
should be comprehensive and gradual. The modern and 
optimal approach to treatment is the use of surgical and con-
servative treatment, searching new and improving existing 
treatments, monitoring the effectiveness of infertility therapy 
and preventing the progression of genital endometriosis. The 
use of assisted reproductive technologies is considered to 
be a progressive direction in the treatment of endometriosis-
associated infertility.
Intrauterine insemination (IUI) is recommended for young 
women with uterine tubes and a regular ovulatory cycle, in 
the absence of significant abnormalities in the man's spermo-
gram. To restore reproductive function in women with genital 
endometriosis in unsuccessful attempts at IUI, impaired fal-
lopian tubal patency and, or in the presence of male infertility, 
superovulation stimulation is used to obtain a large number 
of follicles, remove eggs from them, and use them in assisted 
reproductive technology programs. The use of ART methods 
is also effective in women over 35 years. IVF is a first-line 
therapy in women with endometriosis-associated infertility 
[23, 24]. Pregnancy after IVF in women with genital endo-
metriosis occurs much less frequently than in women with 
other factors of female infertility, which in turn is associated 
with a reduced percentage of fertilized cells, implantation, a 
small number of oocytes [25]. The probability of pregnancy 
depends on the extent of the process, in particular in women 
with severe endometriosis, pregnancy occurs less frequently 
than in women with mild disease [24].
Retrospective meta-analyzes showed that the presence 
of endometrium on the ovary during the stimulation protocol 
in infertility women on the background of ingenious endo-
metriosis with severity degree I–II of the disease, do not 
affect the number of eggs obtained, fertilization factors and 
quality of embryos, but women with severity degrees III–IV 
the disease have lower rates of pregnancy and live birth [26].
Surgical treatment of endometrioid cysts as a "gold 
standard" is used to remove endometrioid heterotopias and 
diagnose the stage of endometriosis. After therapy, access 
during transvaginal puncture is improved and the toxic effect 
of endometrioid content on the oocyte is reduced, but the 
disadvantage of this method is the reduction of ovulatory 
reserve, because along with endometrioid cyst the doctor 
removes healthy ovarian tissue, also possible postoperative 
complications, economic costs and low level of evidence 
of a positive impact on the outcome of IVF may occur [27].
In order to preserve the ovarian reserve of the ovaries 
and remove the endometrioid content before the IVF protocol, 
a relatively new method of treatment has been proposed – 
sclerotherapy of endometrioid cysts [28]. This procedure is 
performed by transvaginal puncture of the cyst and aspiration 
of its content under the control of transvaginal ultrasound, 
introduction into the capsule of the cyst (without violating its 
integrity) sclerosing solution, followed by aspiration. Due to 
the action of sclerosant in the endometrium, inflammatory 
and fibrosis processes are triggered, which leads to oblitera-
tion of the cyst [29]. This procedure is performed for several 
minutes and is performed without general anesthesia. The 
advantages of the method are: minimally invasive, acces-
sible, safe, low frequency of postoperative complications, 
reduction of pain, preservation of ovarian ovulation and 
improved access to the ovary during the oocyte aspira-
tion. Data from retrospective studies indicate that patients 
who underwent sclerotherapy before the controlled ovarian 
stimulation protocol had more follicles and eggs than patients 
who underwent laparoscopic cystectomy, but there is no dif-
ference in the rates of pregnancy [15].
The choice of sclerosant and its effectiveness remain a 
debatable and important issue today in the method of sclero-
therapy. A considerable number of sclerosing substances 
has been proposed, the potential of which is being studied. 
The main requirements for these agents are: reduction in the 
number of recurrences of endometrioid cysts and safety, ie 
the necessary minimal impact on the surrounding ovarian 
tissues to maintain ovulatory reserve. Among the solutions 
used as a sclerosant, ethyl alcohol is most often used, and an 
alcohol extract of the Antiflazide, Solcovagin, methotrexate 
is also used [30].
The ethanol solution (after pre-aspiration of the endome-
trioid content of the cyst) is installed in a volume of 50–100 % 
of the size of the cyst under ultrasound control. Ethanol has a 
cytotoxic effect, causes dehydration of cells and the produc-
tion of mediators of inflammation and fibrosis. According to 
various studies, the average recurrence rate after the use 
of this sclerosant is 14.9 %, and varies depending on the 
method of procedures. With partial aspiration of the solu-
tion, recurrences were observed in 13.3 % of women, with 
complete aspiration of ethanol – in 32.1 % of women [31].
When sclerotherapy with methotrexate using 30 mg of 
methotrexate diluted in saline 100:1 and sclerotherapy with 
tetracycline, a low recurrence rate is observed, but these 
drugs adversely affect the quality of eggs [32].
When using as sclerosant drug Antiflazide endometrioma 
content is aspirated and washed with saline, administer 50 % 
of the volume of the cyst Solcovagin drug, which is diluted with 
96 % ethanol in a ratio of 1:20, after exposure to 10 minutes 
the contents are aspirated again and administer 15–20 % 
of the volume of the alcohol extract of the Antiflazide drug. 
In the postoperative period for 3 months prescribe hormone 
therapy with antiandrogenic effect and oral administration of 
alcohol extract of the Proteflazide drug three times a day for 
1 month. After sclerotherapy there is a decrease in serum 
levels of CA-125 and 100 % of patients show a decrease in 
pain. Thus, sclerotherapy is an alternative method of choice 
for the treatment of endometrioid cysts, especially recurrent 
before IVF protocols [30].
Given the negative impact of endometriosis on a woman's 
reproductive function, folliculogenesis and egg quality in 
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particular, pregravid preparation before the ART protocol is 
extremely important. The use of inositol-containing drugs 
(“FT500 Plus”) is considered one of the newer approaches 
in the pregravid preparation of patients with endometriosis-
associated infertility [33]. The mechanism of action of inositol 
is aimed at improving the antioxidant defense system, and 
reducing the effects of oxidative stress, which improves the 
quality of eggs, and in the future increases the chances of 
positive attempts in ART.
CONCLUSIONS. Clearly, the tactics of treatment of 
patients with endometriosis who are planning a pregnancy 
and included in ART protocols are different from those who 
believe that they have performed reproductive function. 
Surgical treatment leaves a fairly high risk of recurrence of 
the disease and in most cases adversely affects the state of 
the ovarian reserve, deteriorating the quality of ovogenesis, 
which is critical for patients wishing to become pregnant. A 
new technique and a good alternative to open surgical tactics 
for the treatment of ovarian endometriosis is the method of 
sclerotherapy of endometrioid cysts, which has a number 
of advantages: minimally invasive, accessible, eliminating 
the risk of postoperative complications, reducing the risk 
of recurrence of endometrioid cysts and most importantly – 
the preservation of a woman's ovarian reserve. It has been 
shown that the use of aspiration sclerotherapy in women 
with endometriosis before IVF increases the effectiveness 
of ART compared with the use of surgical treatment, and 
high-quality pre-pregnancy training (“FT500 Plus”) improves 
the quality of eggs.
PROSPECTS FOR FURTHER RESEARCH. Despite the 
large amount of existing scientific research and proposed 
theories on the development and impact of endometriosis on 
the reproductive system and its functionality in this disease, it 
is still necessary to study in more detail the qualitative impact 
of endometrioid cysts on the quality of folliculogenesis and 
eggs in infertile women in IVF protocols. Since the method 
of sclerotherapy of endometrioid cysts is a relatively new 
method of treatment, it remains necessary to investigate 
the morphological features of the wall of endometrioid 
cysts depending on the selected method of sclerotherapy 
with further evaluation of its effectiveness and to study the 
quality of sclerosing properties (degree of sclerosis of the 
epithelial lining and subepithelial stroma, the percentage of 
recurrences, restoration of ovarian function).
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